Paul Hastings Advised Corcept Therapeutics in its $145.4 Million Tender Offer

Paul Hastings LLP advised Corcept Therapeutics Incorporated, a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the hormone cortisol, in its $145.4 million issuer tender offer for common stock.

Partners Jeff Hartlin and Samantha Eldredge led the Paul Hastings team, which also included associates Jenna Barba and Nina John.